WOODCLIFF LAKE, NJ, Oct. 19, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. EGRX (“Eagle” or the “Company”) today announced that the Company will host an Investor Day on Tuesday, December 6, 2022 at 8:00 am ET at the Lotte New York Palace Hotel.

The program will provide an opportunity for an in-depth look at the company’s hospital products, including CAL02 and BARHEMSYS^® and BYFAVO^®and ENA-001 from Enalare. Key speakers will include Scott Tarriff, President and Chief Executive Officer, senior members of Eagle’s clinical and commercial teams, and notable Key Opinion Leaders, who will discuss the scientific rationale and potential unmet medical need for each pipeline asset and commercial product.

The audience will have the opportunity to ask questions after the presentations.

Pre-registration is required for this event. Institutional investors and analysts are asked to do so RSVP via this link to participate.

A webcast of this event will be available through the company’s website at www.eagleus.comunder the Investors section.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing and distribution. Eagle is committed to developing innovative medicines that lead to meaningful improvements in patients’ lives. Eagle’s commercialized products include Vasopressin and PEMFEXY^®RYANODEX^®BENDEKA^®BELRAPZO^®TREAKISYM^® (Japan) and BYFAVO^® and BARHEMSYS^® Through its wholly owned subsidiary, Acacia Pharma Inc., Eagle’s oncology and CNS/metabolism critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. For more information, visit Eagle’s website at www.eagleus.com.

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com